CytomX Therapeutics (CTMX) Current Leases (2019 - 2026)

CytomX Therapeutics (CTMX) has 8 years of Current Leases data on file, last reported at $2.9 million in Q1 2026.

• Quarterly Current Leases fell 46.04% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 46.04% YoY) and the FY2025 annual result came in at $4.2 million, down 17.59% from the prior year.
• Current Leases retreated to $2.9 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $5.6 million in Q3 2025 to a low of $2.9 million in Q1 2026.
• A 5-year average of $4.5 million and a median of $4.5 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases climbed 12.82% — and 2026, when it tumbled 46.04%.
• Tracing CTMX's Current Leases over 5 years: stood at $4.1 million in 2022, then advanced by 12.42% to $4.6 million in 2023, then grew by 12.12% to $5.1 million in 2024, then slipped by 17.59% to $4.2 million in 2025, then sank by 32.64% to $2.9 million in 2026.
• The last three Current Leases figures came in at $2.9 million (Q1 2026), $4.2 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.